Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Abstract Background Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown. Methods We assessed 48 week changes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of antimicrobial chemotherapy 2021-09, Vol.76 (9), p.2380-2393
Hauptverfasser: González-Cordón, Ana, Assoumou, Lambert, Moyle, Graeme, Waters, Laura, Johnson, Margaret, Domingo, Pere, Fox, Julie, Stellbrink, Hans-Jürgen, Guaraldi, Giovanni, Masiá, Mar, Gompels, Mark, De Wit, Stephane, Florence, Eric, Esser, Stefan, Raffi, François, Behrens, Georg, Pozniak, Anton, Gatell, José M., Martínez, Esteban
Format: Artikel
Sprache:eng
Schlagworte:
Adiponectin
Cardiovascular Diseases
Heart Disease Risk Factors
Heterocyclic Compounds, 3-Ring - therapeutic use
HIV Infections - complications
HIV Infections - drug therapy
Humans
Infectious Diseases
Life Sciences
Life Sciences & Biomedicine
Lipopolysaccharide Receptors
Microbiology
Oxazines
Pharmacology & Pharmacy
Piperazines
Pyridones
Risk Factors
Ritonavir - administration & dosage
Science & Technology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown. Methods We assessed 48 week changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin resistance, hypercoagulability, heart failure, myocardial injury, and glomerular and tubular kidney injury. Results Of 415 PLWH randomized in the NEAT022 study, 313 (75.4%) remained on allocated therapy and had paired samples available. Soluble CD14 (–11%, P 
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkab158